147 results on '"Kyi, Chrisann"'
Search Results
2. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
3. Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer
4. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1
5. A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
6. Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
7. Mitogen-Activated Protein Kinase Driven Rare Gynecologic Cancers and Evolving Therapeutic Targets
8. Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
9. Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers
10. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
11. A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers
12. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer
13. Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series
14. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
15. Supplementary Table S3 from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
16. Supplementary Figure S3 from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
17. Data from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
18. Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
19. Emerging Biomarkers During Clinical Development of Anti-CTLA4 Antibody Therapy
20. Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1
21. Supplementary Figure 1 from Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
22. Supplementary Figure Legend and Table 1 from Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
23. Data from Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
24. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
25. Figure S3 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
26. Table S2 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
27. 23/#722 Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies
28. Checkpoint blocking antibodies in cancer immunotherapy
29. Abstract 3578: Optimization of shared neoantigen vaccine design to increase vaccine potency: From bench to bedside and back
30. Abstract 4159: Lower doses of self-amplifying mRNA drive superior neoantigen-specific CD8 T cell responses in cancer patients versus high doses
31. A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056).
32. Dysfunctional CD8+ T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC).
33. Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC).
34. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
35. Emerging Biomarkers During Clinical Development of Anti-CTLA4 Antibody Therapy
36. Pattern of disease and response to pembrolizumab in recurrent cervical cancer
37. Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
38. Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
39. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
40. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
41. 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies
42. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer
43. Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies.
44. Pattern of disease in recurrent cervical cancer associated with response to pembrolizumab.
45. Gastric-type adenocarcinoma of the cervix: Genomic drivers and clinical outcomes.
46. Basket study of the oral progesterone antagonist onapristone ER in women with progesterone receptor positive (PR+) recurrent granulosa cell tumor (GCT), low-grade serous ovarian cancer (LGSOC), or endometrioid endometrial cancer (EEC).
47. A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.
48. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
49. Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
50. The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.